Mass Accumulation Rate (MAR) as a Predictive Biomarker in Multiple Myeloma
Stopped Insufficient pace of enrollment due to changes in MM SOC practices
Conditions
- Multiple Myeloma in Relapse
Sponsor
Travera Inc
Collaborators
- [object Object]
- [object Object]
- [object Object]
- [object Object]